3. CoreValve US Pivotal Trial High-Risk Arm

4. Device and Access Routes

5. End Points

6. Patient Eligibilitya

7. Study Disposition

8. Baseline Demographics

9. Results 1 Year All-Cause Mortality

10. Results Noninferiority and Superiority

11. Results 2-Year All-cause Mortality (Preliminary Results)

12. Clinical Patient Outcomes

13. Results All Stroke

14. Secondary End Points

15. 1-Year MACCE

16. Other End Points

17. Paravalvular Regurgitation

18. Subgroup Analysis 1 Year

19. Subgroup Analysis 1 Year (cont)

20. Conclusion

21. CoreValve US Pivotal Trial In Context

22. What Did We Learn?

23. Surgical Outcomes

24. Patient Selection What Is High Risk?

25. Key Inclusion Criteria

26. Study Population – In Context

27. Expanded Patient Population

28. Loss to Follow-Up: Sensitivity Analyses

29. Future TAVR vs SAVR Trial Design Considerations

30. TAVR in Community Practice

31. The TVT Registry

32. TVT 1-Year Outcomesa

33. TAVR Device Comparison Trials

34. CHOICE Key Outcomes

35. CHOICE Clinical Implications

36. TAVR in Clinical Practice: Moving Forward

37. Abbreviations

38. Abbreviations (cont)

39. References

40. References (cont)